Study of Inhibitor of DNA binding 3 (ID3) immunohistochemical marker in Burkitt lymphoma

Karthiga, D (2020) Study of Inhibitor of DNA binding 3 (ID3) immunohistochemical marker in Burkitt lymphoma. Masters thesis, Christian Medical College, Vellore.


Download (5MB) | Preview


AIMS AND OBJECTIVES: 1. To assess the frequency of ID3 mutation in Burkitt lymphoma by using immunohistochemical surrogate during January 2012 to December 2018. 2. To compare the clinicopathologic parameters of ID3 positive and negative Burkitt lymphoma. MATERIALS AND METHODS: Ours is a retrospective observational study. We analysed the clinicopathologic features of BL diagnosed on bone marrow and lymph nodes in our institute over 7 years. A total of 59 cases were analysed for all the clinicopathological features of BL and blocks were available in only 46 cases. Of the 59 cases, 46 were lymph node biopsies and 13 were bone marrow biopsies. The study data were summarized using descriptive statistics. Pearson’s Chi square and Fisher’s exact test were used to evaluate associations between categorical variables using SPSS software to assess any statistical significance. RESULTS: ID3 immunohistochemistry was done in 46/59 cases. There were 20 ID3 positive and 26 ID3 negative BL cases. The calculated frequency of ID3 mutation in our population was 56.52%. The median age of patients in ID3 negative group was 8 years with male predominance. There was no statistically significant association between the histomorphological and immunohistochemical features of BL between ID3 positive and negative cases except for bone marrow involvement (P=0.432), perinodal extension (P=0.039) and the proportion of BCL6 positive cells (P=<0.009). The sensitivity and specificity could not be computed owing to the small subset of cases in the comparison group.

Item Type: Thesis (Masters)
Additional Information: 201713355
Uncontrolled Keywords: BL – Burkitt lymphoma, ID3 – Inhibitor of DNA binding 3.
Subjects: MEDICAL > Pathology
Depositing User: Subramani R
Date Deposited: 29 Jan 2021 18:06
Last Modified: 29 Jan 2021 18:06

Actions (login required)

View Item View Item